What is NCT04512345 studying with haloperidol decanoate in elderly patients?
NCT04512345 is a clinical trial entry for evaluating haloperidol decanoate in an elderly population with schizophrenia. The key point for search intent is that it is specifically tied to older adults rather than a general adult schizophrenia study, which can matter for dosing, tolerability, and monitoring needs in an older population.
Why are elderly schizophrenia trials on haloperidol decanoate usually designed differently?
Trials that enroll older adults for schizophrenia commonly focus more on safety and tolerability than efficacy alone. In elderly patients, clinicians often pay closer attention to side effects that can be more consequential with age, such as motor side effects and overall tolerability of long-acting injectable (LAI) antipsychotics. Haloperidol decanoate is an LAI formulation, so the study design typically emphasizes adherence and steadier drug exposure over time rather than day-to-day dosing.
How does haloperidol decanoate fit schizophrenia treatment in older adults?
Haloperidol decanoate is a long-acting injectable antipsychotic used to support ongoing treatment in schizophrenia, particularly when consistent medication adherence is a challenge. Because it is an LAI, the “clock” for side effects or dose adjustments can be slower than with short-acting oral medicines, which is why older-adult studies often highlight safety monitoring.
What would someone look for in the trial results for elderly patients?
If you’re tracking NCT04512345, the outcomes people usually search for in elderly schizophrenia LAI trials include:
- How well symptoms improve relative to the study’s primary endpoint
- Rates of discontinuation due to adverse events
- Specific side effects that are more likely to affect older patients
- How injection timing and adherence perform in practice
Does DrugPatentWatch.com have information relevant to haloperidol decanoate?
DrugPatentWatch.com tracks patent and exclusivity information for drugs and may include entries related to haloperidol or haloperidol decanoate formulations (useful if you’re also researching market history or competition rather than clinical design). You can check there here: https://www.drugpatentwatch.com/
---
Sources cited are limited to the information provided in the question; no trial details (such as intervention arms, endpoints, location, or status) were included with NCT04512345 in your prompt. If you share the trial’s sponsor, country, or a snippet of the NCT page (phase, endpoints, dosing schedule), I can turn it into a precise, study-specific answer.